Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda

Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation. We report a case of rifampicin resistant Mycobacterium tub...

Descripción completa

Detalles Bibliográficos
Autores principales: Ssengooba, Willy, Komakech, Kevin, Namiiro, Sharon, Byabajungu, Henry, Nalunjogi, Joanitah, Katagira, Winceslaus, Kimuli, Ivan, Joloba, Moses L, Adakun, Susan, Nakiyingi, Lydia, Torrea, Gabriela, Kirenga, Bruce J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592849/
https://www.ncbi.nlm.nih.gov/pubmed/34816021
http://dx.doi.org/10.1016/j.jctube.2021.100286
_version_ 1784599567424028672
author Ssengooba, Willy
Komakech, Kevin
Namiiro, Sharon
Byabajungu, Henry
Nalunjogi, Joanitah
Katagira, Winceslaus
Kimuli, Ivan
Joloba, Moses L
Adakun, Susan
Nakiyingi, Lydia
Torrea, Gabriela
Kirenga, Bruce J
author_facet Ssengooba, Willy
Komakech, Kevin
Namiiro, Sharon
Byabajungu, Henry
Nalunjogi, Joanitah
Katagira, Winceslaus
Kimuli, Ivan
Joloba, Moses L
Adakun, Susan
Nakiyingi, Lydia
Torrea, Gabriela
Kirenga, Bruce J
author_sort Ssengooba, Willy
collection PubMed
description Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation. We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection.
format Online
Article
Text
id pubmed-8592849
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-85928492021-11-22 Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda Ssengooba, Willy Komakech, Kevin Namiiro, Sharon Byabajungu, Henry Nalunjogi, Joanitah Katagira, Winceslaus Kimuli, Ivan Joloba, Moses L Adakun, Susan Nakiyingi, Lydia Torrea, Gabriela Kirenga, Bruce J J Clin Tuberc Other Mycobact Dis Article Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation. We report a case of rifampicin resistant Mycobacterium tuberculosis whose rifampicin resistance was missed by Xpert MTB/RIF Assay G4 but detected by the Xpert MTB/RIF Ultra assay at different time points leading to increased delays for MDR-TB treatment initiation at Mulago Hospital, Kampala, Uganda. Our case report compels greater urgency in accelerating the transition to the newer assay, Ultra, to benefit from higher sensitivity of rifampicin resistance detection. Elsevier 2021-11-06 /pmc/articles/PMC8592849/ /pubmed/34816021 http://dx.doi.org/10.1016/j.jctube.2021.100286 Text en © 2021 The Authors. Published by Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Ssengooba, Willy
Komakech, Kevin
Namiiro, Sharon
Byabajungu, Henry
Nalunjogi, Joanitah
Katagira, Winceslaus
Kimuli, Ivan
Joloba, Moses L
Adakun, Susan
Nakiyingi, Lydia
Torrea, Gabriela
Kirenga, Bruce J
Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_full Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_fullStr Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_full_unstemmed Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_short Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda
title_sort rifampicin susceptibility discordance between xpert mtb/rif g4 and xpert ultra before mdrt-tb treatment initiation: a case report from uganda
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8592849/
https://www.ncbi.nlm.nih.gov/pubmed/34816021
http://dx.doi.org/10.1016/j.jctube.2021.100286
work_keys_str_mv AT ssengoobawilly rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT komakechkevin rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT namiirosharon rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT byabajunguhenry rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT nalunjogijoanitah rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT katagirawinceslaus rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT kimuliivan rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT jolobamosesl rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT adakunsusan rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT nakiyingilydia rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT torreagabriela rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda
AT kirengabrucej rifampicinsusceptibilitydiscordancebetweenxpertmtbrifg4andxpertultrabeforemdrttbtreatmentinitiationacasereportfromuganda

Ejemplares similares